NEW YORK (GenomeWeb News) – Fluidigm said in its Form 10-Q last week that it will pay Life Technologies $1.0 million as part of a cross-license agreement reached between Fluidigm and Life Tech's Applied Biosystems business. Life Tech notified Fluidigm in mid-October that the payment is due and payable under the license agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.